Differential expression of Toll-like receptors in murine peritoneal macrophages in vitro on treatment with cisplatin

International Immunology

Volumn 19, Issue 5, 2007, Pages 635-643

  Tarang, Shikha ^a   Sodhi, Ajit ^a   Chauhan, Puja ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Cisplatin; Macrophage activation; Toll like receptors

Indexed keywords

CISPLATIN; GAMMA INTERFERON; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ARTICLE; BAGG ALBINO MOUSE; CANCER THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; CISPLATIN; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; IMMUNOPRECIPITATION; INTERFERON REGULATORY FACTOR-3; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 34447504865     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxm029     Document Type: Article

References (50)

1. Hoffmann, J. A., Kafatos, F. C., Janeway, C. A. and Ezekowitz, R. A. 1999. Phylogenetic perspectives in innate immunity. Science 284:1313.
2. Medzhitov, R., Preston-Hurlburt, P. and Janeway, C. A. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394.
3. Aderem, A. and Ulevitch, R. J. 2000. Toll-like receptors in the induction innate immune response. Nature 406:782.
4. Rock, F. L., Hardiman, G., Timans, J. C., Kastelein, R. A. and Bazan, J. F. 1998. A family of human receptors structurally related to Drosophila Toll. Proc. Natl Acad. Sci. USA 95:588.
5. Akira, S. and Hemmi, H. 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immonol. Lett. 85:85.
6. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M. and Hoffmann, J. A. 1996. The dorsoventral regulatory gene cassette spatzel/Toll/ cactus controls the potent anti-fungal response in Drosophila adults. Cell 86:973.
7. Beg, A. A. 2002. Endogenous ligands of Toll-like receptors: Implications for regulating inflammatory and immune responses. Trends Immunol. 23:509.
8. Takeda, K., Kaisho, T. and Akira, S. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335.
9. Xu, Y., Tao, X., Shen, B. et al. 2000. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 408:111.
10. Khan, J. A., Brint, E. K., O'Neill, L. A.J. and Tong, L. 2004. Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J. Biol. Chem. 279:31664.
11. McGettrick, A. F. and O'Neill, L. A.J. 2004. The expanding family of MyD88-like adaptors in TLR signal transduction. Mol. Immunol. 41:577.
12. Karen, M. H. and Turchi, J. J. 1999. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 59:3077.
13. Bajetta, E., Stani, S. C., De Candis, D. et al. 2003. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann. Oncol. 14:242.
14. Singh, R. A. and Sodhi, A. 1998. Antigen presentation by cisplatin-activated macrophages: Role of soluble factor(s) and second messengers. Immunol. Cell Biol. 76:513.
15. Singh, R. K., Sodhi, A. and Singh, S. M. 1991. Production of interleukin and tumour necrosis factor by cisplatin treated murine peritoneal macrophages. Nat. Immun. Cell Growth Regul. 10:105.
16. Sodhi, A. and Pai, K. 1992. Increased production of interleukin-1 and tumor necrosis factor alpha by human monocytes treated in vitro with cisplatin or other biological response modifiers. Immunol. Lett. 34:183.
17. Sodhi, A. and Gupta, P. 1986. Increased production of hydrogen peroxide (H2O2) and superoxide anion (O-2) by murine macrophages in vitro after cisplatin treatment. Int. J. Immunopharmacol. 8:709.
18. Singh, R. A. and Sodhi, A. 1998. Cisplatin treated macrophages produce oncostatin M: Regulation by serine/threonine and protein tyrosine kinase/ phosphatase and Ca2+/calmadulin. Immunol. Lett. 62:159.
19. Shishodia, S., Srivastava, A. and Sodhi, A. 1998. Protein kinase C: A potential pathway of macrophage activation with cisplatin. Immunol. Lett. 61:179.
20. Shishodia, S., Sodhi, A. and Srivastava, A. 1997. Cisplatin induced activation of murine bone marrow-derived macrophages require protein tyrosine phosphorylation. Int. J. Immunopharmacol. 19:683.
21. Taylor, P. R., Maritnez-Pomares, L., Stacey, M., Lin, H. H., Brown, G. D. and Gordon, S. 2005. Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23:901.
22. Ozinsky, A., Underhill, D. M., Fontenot, J. D. et al. 2000. The repertoire of pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl Acad. Sci. USA 97:13766.
23. Maung, A. A., Fujimi, S., Miller, M. L., MacConmara, M. P., Mannick, J. A. and Lederer, J. A. 2005. Enhanced TLR4 reactivity following injury is mediated by increased p38 activation. J. Leukoc. Biol. 78:565.
24. Rao, K. M. 2001. MAP kinase activation in macrophages. J. Leukoc. Biol. 69:3.
25. Wajant, H., Henkler, F. and Scheurich, P. 2001. The TNF-receptor-associated factor family: Scaffold molecules for cytokine receptors, kinases and their regulators. Cell. Signal. 13:389.
26. Nilsen, N., Nonstad, U., Khan, N. et al. 2004. Lipopolysaccride and double-stranded RNA up regulate Toll-like receptor 2 independently of myeloid differentiation factor 88. J. Biol. Chem. 279:39727.
27. MacKay, R. J., King, R. R., Dankert, J. R., Reis, K. J. and Skelley, L. A. 1991. Cytotoxic tumor necrosis factor activity produced by equine alveolar macrophage: Preliminary chracterization. Vet. Immunol. Immunophthol. 29:15.
28. Jiang, W., Li, J., Gallowitsch-Pureta, M., Tracey K. J. and Pisetsky, D. S. 2005. The effects of CpG DNA on HMGB1 release by murine macrophages cell lines. J. Leukoc. Biol. 78:930.
29. Sodhi, A. and Sethi, G. 2003. Involvement of MAP kinase signal transduction pathway in UV-B induced activation of macrophages in vitro. Immunol. Lett. 90:123.
30. Brouet, I. and Ohshima, H. 1995. Curcumin, an anti-tumor promotor and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem. Biophy. Res. Commun. 206:533.
31. Heil, F., Ahmed-Nejad, P., Hemmi, H. et al. 2003. The toll-like receptor 7 (TLR7) specific stimulus Ioxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 33:2987.
32. O'Neill, L. A.J. 2005. How Toll-like receptor signal: What we know and what we don't know. Curr. Opin. Immunol. 17:1.
33. An, H., Yu, Y., Zhang, M. et al. 2002. Up regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-kappaB, ERK and p38 MAPK signal pathways. Immunol. Lett. 81:169.
34. Takeda, K., Kaisho, T. and Akira, S. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17:1.
35. Werts, C., Tapping, R. I., Mathison, J. C. et al. 2001. Leptospiral lipopolysaccharide activates cells through TLR2-dependent mechanism. Nat. Immunol. 2:346.
36. Poltorak, A., Xiaolong, H., Smimova, I. et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutation in tlr4 gene. Science 282:2085.
37. Takeuchi, O., Hoshino, K., Kawai, T. et al. 1999. Differential roles of TLR2 and TLR4 in recognition of gram negative and gram positive bacterial cell wall components. Immunity 11:443.
38. Ohashi, K., Burkart, V., Flohe, S. and Kolb, H. 2000. Cutting edge: Heat shock Protein 60 is putative endogenous ligand of the Toll-like receptor 4 complex. J. Immunol. 164:558.
39. Gao, B. and Tsan, M. F. 2003. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp 70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J. Biol. Chem. 278:179.
40. Takeda, K. 2005. Toll-like receptors and their adaptors in innate immunity. Curr. Med. Chem. 4:3.
41. Hyashi, F, Smith, K. D., Ozinsky, A. et al. 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099.
42. Hemmi, H., Takeuchi, O., Kawai, T. et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740.
43. Lee, J., Chuang, T. H., Redecke, V. et al. 2003. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl Acad. Sci. USA 100:6646.
44. Anderson, K. V. 2000. Toll-signaling pathways in the innate immune response. Curr. Opin. Immunol. 12:13.
45. Kaisho, T, Takeuchi, O., Kawai, T., Hoshino, K. and Akira, S. 2001. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J. Immunol. 166:5688.
46. Yamamoto, M., Sato, S., Mori, K. et al. 2002. Cutting edge: A novel Toll/IL-1 receptor domain containing adaptor that preferentially activates the IFN-beta promoter in the toll-like receptor signaling. J. Immunol. 169:6668.
47. Kammanadiminti, S. J., Mann, B. J., Dutil, L. and Chadee, K. 2004. Regulation of Toll-like receptor 2 expression by the Gal-lectin of Entamoeba histolytica. FASEB 18:155.
48. Rosenberg, B., Vancamp, L. and Krigas, T. 1965. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698.
49. Okamoto, M. and Sato, M. 2003. Toll-like receptor signaling in anticancer immunity. J. Med. Invest. 50:9.
50. Ahmed, S. U., Okamoto, M., Oshikawa, T. et al. 2004. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-32, a streptococcal immunopotentiator: Involvement of Toll like receptor 4. J. Immunother. 27:432.